1. Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis
- Author
-
Ee Min Yeoh, Jun Zhu, Kensei Tobinai, and Yoshinobu Maeda
- Subjects
Oncology ,China ,Cancer Research ,Angioimmunoblastic T-cell lymphoma ,medicine.medical_specialty ,Poor prognosis ,03 medical and health sciences ,0302 clinical medicine ,First line therapy ,Japan ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Single agent ,Prospective Studies ,Retrospective Studies ,business.industry ,Lymphoma, T-Cell, Peripheral ,Pralatrexate ,Hematology ,medicine.disease ,Peripheral T-cell lymphoma ,Aminopterin ,Lymphoma ,Pooled analysis ,030220 oncology & carcinogenesis ,Neoplasm Recurrence, Local ,business ,030215 immunology ,medicine.drug - Abstract
Angioimmunoblastic T-cell lymphoma (AITL) is a histological subtype of peripheral T-cell lymphoma associated with a poor prognosis. This post-hoc pooled analysis aims to provide insight about the efficacy of pralatrexate monotherapy in a subset of twenty-nine patients with relapsed or refractory (r/r) AITL drawn from two prospective registration trials completed in China and Japan. After a median of two prior lines of therapy, an overall response rate of 52% (15/29 patients; 95% CI 0.34, 0.70) was demonstrated. The estimated median duration of response, progression free survival (PFS) and overall survival (OS) were 6.4 months (196 days), 5.0 months (151 days), and 18.0 months (548 days), respectively. Grades 1-3 mucositis was observed in twenty-three patients (79.3%); and hemato-toxicity in twenty-six (89.7%) patients. Results of this analysis corroborate with data from two previously reported US retrospective cohorts, supporting the potential benefits of pralatrexate monotherapy in patients with r/r AITL.
- Published
- 2020